When it comes to PNH, the immune system's complement system mistakenly attacks and destroys red blood cells — a process called hemolysis. Complement inhibitors are medications designed to block this process, helping to protect red blood cells and reduce the risk of dangerous blood clots.
The FDA-approved complement Show Full Answer
When it comes to PNH, the immune system's complement system mistakenly attacks and destroys red blood cells — a process called hemolysis. Complement inhibitors are medications designed to block this process, helping to protect red blood cells and reduce the risk of dangerous blood clots.
The FDA-approved complement inhibitors for PNH include:
- Eculizumab (Soliris) and its biosimilars (Bkemv, Epysqli)
- Ravulizumab (Ultomiris)
- Crovalimab (PiaSky)
- Pegcetacoplan (Empaveli)
- Iptacopan (Fabhalta)
- Danicopan (Voydeya) These medications have made a significant difference — a 2021 study found that people taking complement inhibitors had an 82% chance of surviving 20 years, compared to 69% for those who were never treated.
It's worth knowing that even on complement inhibitors, there's still a risk of breakthrough hemolysis and blood clots, so some people may also need blood thinners alongside their treatment. Always talk with your doctor about which option is the best fit for your specific situation.
July 1
Continue with Facebook
Continue with Email
Join
Your Privacy Choices
